Trading JPM Week: Deals and Guidance, Not Data

The Problem

Every January, traders who know how to trade ASCO and ESMO show up at the J.P. Morgan Healthcare Conference expecting a data catalyst, and they miss the entire move. JPM week is not a data event. There are no abstracts, no late-breakers, no plenary halls. The catalysts are deals and guidance: a small biotech pre-announces a beat, or Big Pharma announces a bolt-on acquisition. If you are watching for a clinical readout, you are watching the wrong channel.

JPM Is Not ASCO

Medical-data conferences like ASCO and ESMO move stocks on abstract release day, when trial data drops online. JPM is a different animal. It is the biggest deal-making and guidance event of the biotech year. Three things move stocks during the week of January 11-14, 2027 in San Francisco:

Catalyst	What it looks like
Q4 / 2027 guidance pre-announcements	A company pulls forward good news or warns on the year ahead
M&A and licensing announcements	A buyout or partnership, often leaked in the week prior
Partnership rumors	Deal chatter that runs a small cap 30% before it is confirmed

The medical-data conference guide covers the abstract rhythm. This guide covers the deal rhythm, because that is what actually moves stocks in January.

One nuance trips up newcomers: “guidance” at JPM does not mean earnings guidance. Most small and mid-cap biotechs are pre-revenue, so their guidance is cash runway commentary, pipeline timeline updates, and partnership readouts, not EPS. When a biotech “pre-announces” at JPM, it is usually confirming that the cash runway holds through the next catalyst, or signaling that a raise is coming. Read it through that lens.

Step 1: Mark the Dates

The 45th Annual J.P. Morgan Healthcare Conference runs January 11-14, 2027 in San Francisco. The positioning window opens in late November, about six weeks before. By the first week of January, most of the re-rating has already started.

What to do: Put January 11-14 on your calendar now. Plan to be fully positioned by the end of the first week of January, not the week of the conference.

Step 2: Screen the “Will They Raise or Get Bought” Cohort

The stocks that move at JPM are small and mid caps with a 2027 catalyst and a cash runway question. A company with less than 18 months of cash and a major readout coming either raises capital (dilution) or gets acquired (premium). JPM week is where both outcomes get telegraphed.

H1 2026 was a $96 billion, 80-deal M&A market, and the typical buyout premium runs 50-100%. Big Pharma has a $300 billion patent-cliff problem to solve this decade, which is why bolt-on acquisitions in the $1-10 billion range are the dominant deal type.

What to do: Screen for sub-$5 billion market cap names with a 2027 PDUFA date or Phase 3 readout and less than 18 months of cash runway. Those are your JPM candidates. The 8-point M&A screen is the filter to run them through.

Step 3: Watch for the Pre-Announcement Tell

The cleanest signal is a change in the presentation schedule. A company that pulls its JPM presentation slot, or adds an unscheduled one, is usually about to pre-announce something: a deal, a data beat, or a guidance raise. The companies do not say this in advance. You read it in the calendar.

What to do: Track the JPM presenter list as it firms up in December. A pulled slot or a surprise add is a signal to research, not to buy blindly. Treat it as a lead, then confirm with the company’s actual announcement.

Step 4: Position-Size the Rumor as Speculation, Not Fact

The week before JPM, deal rumors leak and small caps run on nothing but chatter. Some of those rumors are real; most are not. The danger is buying the rumor at the top and holding into a “no deal” resolution.

What to do: If you trade a JPM rumor, size it like a lottery ticket, not a thesis. The 1-2% per-catalyst rule applies. A rumor-driven run of 30% into the conference is a sell, not a buy, unless a deal is actually announced. For the mechanics of trading an announced deal, see how to trade biotech M&A deal spreads.

Step 5: Sell the JPM Pop

January deals historically get faded. A company that gets bought re-rates to the deal price and stays there; a company that pre-announces a beat often pops and then gives the move back over the following weeks as the January-effect buyers who chased the sector take profits.

The January effect itself is real: biotech broadly rallies into early January as tax-loss selling from December reverses. That re-rating concentrates in JPM week, and it is the reason the sector often peaks right before it fades. The Q4 2026 playbook covers the tax-loss mechanics in detail.

What to do: If a position pops on a JPM announcement, take the gain. Do not hold into February expecting the January bid to keep paying you.

Common Mistakes

1. Treating JPM like ASCO and waiting for a data readout. There is no data. The move is deals and guidance, and it happens in the week before and during the conference.
2. Buying the rumor the week of JPM. The rumor-driven run happened in December. By JPM week you are the exit liquidity.
3. Chasing a pre-announcement after it is public. The stock already moved on the headline. You are buying the news, not the signal.
4. Holding through February. The January bid fades. The sector-wide rally is seasonal, and the seasonal buyer leaves after the conference.

Final Checklist

• Mark January 11-14, 2027 on the calendar now
• Screen sub-$5B names with 2027 catalysts and under 18 months of cash
• Track the JPM presenter list for pulled or surprise slots
• Size any rumor trade at 1-2%, as speculation
• Sell the JPM pop, do not hold into the February fade

For the data-conference side of the trade, start with how to trade medical conferences like ASCO and ESMO. For the M&A targets that tend to get bought in January, see Big Pharma’s patent-cliff M&A targets and the biotech cycle review. The official conference details live at jpmorgan.com.